Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Examination of remission period in ulcerative colitis patients led to mucosal remission by induction therapy with budesonide rectal foam (AJG511) .

Trial Profile

Examination of remission period in ulcerative colitis patients led to mucosal remission by induction therapy with budesonide rectal foam (AJG511) .

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Budesonide (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms ESCORT
  • Sponsors EA Pharma; Kissei Pharmaceutical
  • Most Recent Events

    • 06 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 03 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top